Cipla is confident of surpassing its FY25 guidance, with supply challenges for Lanreotide expected to ease by Q1FY26. The trade business has stabilised, and a key drug launch is planned for H2 FY26.
Cipla is confident of surpassing its FY25 guidance, with supply challenges for Lanreotide expected to ease by Q1FY26. The trade business has stabilised, and a key drug launch is planned for H2 FY26.